Spots Global Cancer Trial Database for Safety Study of X-82 in Patients With Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Safety Study of X-82 in Patients With Advanced Solid Tumors
Official Title: Phase I, First in Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of X-82 in Patients With Advanced Solid Tumors
Study ID: NCT01296581
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to determine the maximum tolerated dose (MTD) of X-82 as a single agent.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Sarah Cannon Research Institute, Nashville, Tennessee, United States
Contact Details
Name: Gina Courtney, MD
Affiliation: Study PI
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
